Psoriasis Journal Articles

 
 
  • Therapeutics for Adult Nail Psoriasis and Nail Lichen Planus Nail psoriasis and nail lichen planus can be stigmatizing and challenging to treat. This article presents an approach for selecting current topical and systemic therapies, including new biologics.
  • Obesity and Treatment Failure in Biologic-Treated UC Patients How does obesity impact real world response to biological therapy in patients with ulcerative colitis?
  • Psychological Stress and Psoriasis Its long been supposed that psychological stress aggravates psoriasis--but is there any convincing evidence to support this?
  • Janus Kinase Inhibitors: Emerging Applications in Dermatology Learn about the use of Janus kinase inhibitors, which have become promising treatment options for dermatologic conditions such as psoriasis, atopic dermatitis, alopecia areata, vilitigo, and more.
  • The Non-neuronal and Nonmuscular Effects of Botulinum Toxin New research suggests that botulinum neurotoxins may have a much wider range of both dermatological and nondermatological applications than originally thought.
  • Telerheumatology: The VA Experience This study assessed the diagnostic accuracy of telerheumatology as compared with face-to-face visits in a VA rheumatology clinic. Was the telerheumatology process well received by patients?
  • News for Pediatric Healthcare Providers From the FDA Which drugs have been newly developed or indicated for pediatric patients? Find out what there is to know.
  • Health Economics and Clinical Decision Making in Psoriasis While biological treatments for plaque psoriasis are highly effective and safe, they are also expensive. How can we prioritize their use while balancing cost-effectiveness?
  • HLA-Cw6 and Psoriasis What role does the HLA-Cw6 allele play in psoriasis? This review summarizes what we know concerning its relationship to epidemiology, pathogenesis, characteristics, and treatment implications.
  • Dermatologic Reactions to Immune Checkpoint Inhibitors Immune checkpoint inhibitors are a major breakthrough in cancer therapy, but may cause immune-related dermatologic adverse reactions. How do these commonly manifest and how should they be managed?
  • Managing Morbidity and Treatment-Related Toxicity in AS Find out more about the morbidities associated with ankylosing spondylitis and its treatment, and learn how to best manage them.
  • Ixekizumab Treatment for Psoriasis This study presents a comprehensive overview of the efficacy of ixekizumab therapy for moderate-to-severe plaque psoriasis, based on two ixekizumab dosing regimens from pivotal phase III studies.
  • Low Doses of Etanercept to Maintain Remission in PsA Find out how psoriatic arthritis patients who have achieved sustained remission with etanercept may benefit from a dosing interval increase.
  • Brodalumab: A Review of Safety This article reviews the publicly available safety data for brodalumab, an interleukin-17R inhibitor approved for chronic plaque psoriasis. Is its safety profile similar to other IL-17 antagonists?
  • Long-term Efficacy, Safety of Ustekinumab in Refractory CD This study evaluated the long-term efficacy and safety of ustekinumab in anti-TNF refractory Crohn's disease patients.
  • Biologics and Biosimilars for Moderate-to-severe Psoriasis Several biosimilars are now available for biologic therapies used to treat moderate-to-severe plaque psoriasis. This study compares long-term safety, efficacy, and drug survival data on these agents.
  • Efficacy, Safety, and Tolerability of Secukinumab in AS Is secukinumab a safe and effective treatment choice for patients with ankylosing spondylitis?
  • Nonradiographic AS: Clinical and Therapeutic Relevance How is nonradiographic axial spondyloarthritis distinguished from radiographic disease -- and how do management strategies differ?
  • Dietary Change as a Treatment Strategy for Skin Disease This review focuses on five major skin conditions for which dietary change may contribute to treatment--both by eliminating "triggers" and providing benefit.
  • Infections From Ixekizumab in Patients With Psoriasis IL-17A antagonists are increasingly used to treat moderate-to-severe psoriasis, but infections are a concern. This study investigated the incidence and types of infections associated with ixekizumab.